Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and/or human GITR receptor (GITR), including multispecific antibodies that bind, e.g., to OX40 and GITR, and compositions comprising such antibodies. The antibodies disclosed herein modulate OX40 and/or GITR activity e.g., enhance, activate, induce, reduce, deactivate, or inhibit OX40 and/or GITR activity. The present disclosure also provides methods for treating disorders, such as cancer, autoimmune diseases or disorders, or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and/or human GITR and modulates OX40 and/or GITR activity.

Abstract: A synchronization protocol is provided that can be used to resolve synchronization errors encountered while trying to synchronize versions of data objects between a client device and a remote computing system. The protocol includes a client device, in an offline processing mode, handling user interface (“UI”) manipulation actions on one or more UI elements of one or more UI screens. The handling of the UI manipulation actions modifies or creates a local version of a data object stored on the client device. The UI manipulation actions are stored by the client device and sent to the remote computing system. The client device receives a synchronization error notification from the remote computing system. After receiving the notification, the client device displays, in one of the UI screens, the local version of the data object and one or more indications of a synchronization error.

Abstract: In response to a request to present a first user interface to a first user, a first user interface adaptation associated with the first user interface is determined, a first control flag associated with the first user interface adaptation and with a first condition is determined, the first condition based on a value of first master data, and the value of the first master data for the first user is determined, the first control flag is evaluated based on the value of the first master data for the first user. If the first control flag evaluates to True, the first user interface adaptation is applied to the first user interface and the adapted first user interface is presented to the first user and, if the first control flag evaluates to False, the first user interface is presented to the first user.

Abstract: The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.

Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.

Abstract: The instant disclosure provides antibodies that specifically bind to human CTLA-4 and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: Antibodies, particularly humanized and variant antibodies and fragments thereof, which bind to TGF-?1 are provided, recognizing human and mouse TGF-?1, particularly that preferentially bind TGF-?1, including which do not recognize or bind TGF-?2 or TGF-?3. Humanized and variant antibodies provided are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens, and in fibrotic conditions. The anti-TGF-?1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in lymphoid cell-mediated, including T cell-mediated, therapy and/or combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof.

Abstract: Systems and methods to select an object instance from a database storage to archive to an external storage based on an archiving configuration and attribute values of the object instance, transmit the selection to an application associated with the object instance, determine, based on a response received from the application, to archive the object instance, mark the object instance as ready for archiving, identify the object instance as ready for archiving, convert the object instance to an object notation format, transmit the converted object instance to a cloud application for storage in an external storage, in response to a determination that the storage in the external storage is successful, create an index object in the database storage including a subset of fields of the object instance and a link to the converted object instance stored in the external storage, and mark the object instance in the database storage as archived.

Abstract: Antibodies, particularly humanized antibodies and variant antibodies and fragments thereof, which bind to transforming growth factor beta 3 (TGF-?3) are provided, recognizing human and mouse TGF-?3, particularly antibodies and fragments that do not recognize or bind TGF-?1 or TGF-?2. Humanized and variant antibodies are provided which specifically recognize and neutralize TGF-?3 and are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?3, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens, and in fibrotic conditions. The anti-TGF-?3 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in lymphoid cell-mediated, including T cell-mediated, therapy and in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof.

Abstract: A system includes reception of a query input by a user into a user interface, determination, in response to reception of the query, of a plurality of query results, each of the query results associated with a respective object instance of one of a plurality of object types, where the plurality of object types comprise a master data object type and a report object type, and presentation of the plurality of query results to the user, the plurality of query results comprising a first indicator of a first query result associated with an instance of the report object type and a second indicator a second query result associated with an instance of the master data object type, where the first indicator is selectable by the user to cause execution of the instance of the report object type to create a report and presentation of the report to the user, and where the second indicator is selectable by the user to cause retrieval and presentation of the instance of the master data object type to the user.

Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or diminish, deactivate, or suppress OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., diminishes, deactivates, or suppresses OX40 activity.

Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.

Abstract: The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: Disclosed herein are system, method, and computer program product embodiments for extracting customer relationship management (CRM) data from an on-premises database for testing with a cloud-based CRM. The extraction approach simplifies, through the use of a wizard, the selection of relevant customer records and their extraction, along with any dependencies on other records. The extracted records can then be uploaded to the cloud-based CRM for evaluation.

Abstract: The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.

Abstract: A system includes reception of a query input by a user into a user interface, determination, in response to reception of the query, of a plurality of query results, each of the query results associated with a respective object instance of one of a plurality of object types, where the plurality of object types comprise a master data object type and a report object type, and presentation of the plurality of query results to the user, the plurality of query results comprising a first indicator of a first query result associated with an instance of the report object type and a second indicator a second query result associated with an instance of the master data object type, where the first indicator is selectable by the user to cause execution of the instance of the report object type to create a report and presentation of the report to the user, and where the second indicator is selectable by the user to cause retrieval and presentation of the instance of the master data object type to the user.

Abstract: The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.

Abstract: The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.